[Fibroblast growth factor (FGF) endocrines and pulmonary fibrogenesis]

M Ghanem; A Mailleux; B Crestani

doi:10.1016/j.rmr.2023.01.018

[Fibroblast growth factor (FGF) endocrines and pulmonary fibrogenesis]

Rev Mal Respir. 2023 Mar;40(3):239-242. doi: 10.1016/j.rmr.2023.01.018. Epub 2023 Feb 23.

[Article in French]

Authors

M Ghanem¹, A Mailleux², B Crestani³

Affiliations

¹ Inserm Unité 1152, Université Paris Cité, Paris, France. Electronic address: mada.ghanem@inserm.fr.
² Inserm Unité 1152, Université Paris Cité, Paris, France.
³ Inserm Unité 1152, Université Paris Cité, Paris, France; Service de pneumologie A, Hôpital Bichat, AP-HP, Paris, France.

PMID: 36828676
DOI: 10.1016/j.rmr.2023.01.018

Abstract

As key actors in embryogenesis and organogenesis, fibroblast growth factors (FGFs) can assume a protective or an aggravative role in pulmonary fibrosis pathophysiology. Among the FGFs, endocrine FGFs (FGF19, FGF21 and FGF23), are characterized by low affinity to FGF receptors (FGFRs), enabling them to deploy endocrine activity in several organs. More specifically, their anti-fibrotic role has been reported in liver, kidney or myocardial fibrosis. Endocrine FGFs are of growing interest on account of their potential anti-fibrotic role in pulmonary fibrogenesis, as well. In this review, we aim to summarize current knowledge on the protective effects of endocrine FGFs in pulmonary fibrosis.

Keywords: Endocrine FGFs; FGF endocrines; Fibrose pulmonaire; Pathophysiology; Physiopathologie; Pulmonary fibrosis.

Publication types

Review
English Abstract

MeSH terms

Fibroblast Growth Factors / metabolism
Humans
Pulmonary Fibrosis* / etiology

Substances

Fibroblast Growth Factors